Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents
Clinical trial NCT02936752 · COMPLETED
Trial details
- NCT number
- NCT02936752
- Sponsor
- National Cancer Institute (NCI)
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-06-23
- Primary completion
- 2022-11-04
- Enrollment
- 28
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.